283 related articles for article (PubMed ID: 24720805)
21. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
[TBL] [Abstract][Full Text] [Related]
22. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.
McIntyre RS; Tohen M; Berk M; Zhao J; Weiller E
J Affect Disord; 2013 Sep; 150(2):378-83. PubMed ID: 23712026
[TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom.
McKendrick J; Cerri KH; Lloyd A; D'Ausilio A; Dando S; Chinn C
J Psychopharmacol; 2007 Aug; 21(6):588-96. PubMed ID: 17050661
[TBL] [Abstract][Full Text] [Related]
24. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
Szegedi A; Calabrese JR; Stet L; Mackle M; Zhao J; Panagides J;
J Clin Psychopharmacol; 2012 Feb; 32(1):46-55. PubMed ID: 22198448
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.
Bozzatello P; Rocca P; Uscinska M; Bellino S
CNS Drugs; 2017 Sep; 31(9):809-819. PubMed ID: 28741044
[TBL] [Abstract][Full Text] [Related]
26. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.
Kemp DE; Zhao J; Cazorla P; Landbloom RP; Mackle M; Snow-Adami L; Szegedi A
J Clin Psychiatry; 2014 Mar; 75(3):238-45. PubMed ID: 24499969
[TBL] [Abstract][Full Text] [Related]
27. [Asenapine in bipolar disorder: efficacy, safety and place in clinical practice].
Samalin L; Tixeront C; Llorca PM
Encephale; 2012 Jun; 38(3):257-65. PubMed ID: 22726414
[TBL] [Abstract][Full Text] [Related]
28. An update on the treatment of mixed bipolar states: what is new in 2013?
Ouanes S; Chennoufi L; Cheour M
J Affect Disord; 2014 Apr; 158():53-5. PubMed ID: 24655765
[TBL] [Abstract][Full Text] [Related]
29. Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder.
Landbloom RL; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
J Affect Disord; 2016 Jan; 190():103-110. PubMed ID: 26496015
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada.
Lachaine J; Beauchemin C; Mathurin K; Gilbert D; Beillat M
J Med Econ; 2014 Apr; 17(4):296-304. PubMed ID: 24564402
[TBL] [Abstract][Full Text] [Related]
31. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
32. Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder.
Findling RL; Landbloom RL; Szegedi A; Koppenhaver J; Braat S; Zhu Q; Mackle M; Chang K; Mathews M
J Am Acad Child Adolesc Psychiatry; 2015 Dec; 54(12):1032-41. PubMed ID: 26598478
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-analysis of placebo-controlled trials.
Muralidharan K; Ali M; Silveira LE; Bond DJ; Fountoulakis KN; Lam RW; Yatham LN
J Affect Disord; 2013 Sep; 150(2):408-14. PubMed ID: 23735211
[TBL] [Abstract][Full Text] [Related]
34. Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program.
Szegedi A; Zhao J; McIntyre RS
J Affect Disord; 2013 Sep; 150(3):745-52. PubMed ID: 23473546
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.
Niufan G; Tohen M; Qiuqing A; Fude Y; Pope E; McElroy H; Ming L; Gaohua W; Xinbao Z; Huichun L; Liang S
J Affect Disord; 2008 Jan; 105(1-3):101-8. PubMed ID: 17531327
[TBL] [Abstract][Full Text] [Related]
37. Asenapine: a clinical review of a second-generation antipsychotic.
Stoner SC; Pace HA
Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
39. Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice.
Fagiolini A; Forgione RN; Morana B; Maccari M; Goracci A; Bossini L; Pellegrini F; Cuomo A; Casamassima F
Expert Opin Pharmacother; 2013 Mar; 14(4):489-504. PubMed ID: 23356509
[TBL] [Abstract][Full Text] [Related]
40. Quetiapine: a pharmacoeconomic review of its use in bipolar disorder.
Plosker GL
Pharmacoeconomics; 2012 Jul; 30(7):611-31. PubMed ID: 22559293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
